Boston, United States
PepGen, founded in 2018, is a burgeoning player in the Biotechnology industry, headquartered in the United States. The company is on a mission to revolutionize treatment options for genetic neuromuscular and neurological disorders through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform.
PepGen's approach aims to develop a suite of disease-modifying therapeutics that promise to safely and effectively address the root causes of these serious conditions. Their clear focus is underscored by their slogan: "Better Technology. Better Delivery."
As of 01 September 2025, PepGen received a Post IPO Equity investment, although the specific investors were not disclosed. This recent capital infusion signals investor confidence and positions PepGen to advance its research and expand its therapeutic pipeline. For venture capitalists and investors, PepGen represents a promising opportunity to engage with cutting-edge biotechnology innovations addressing unmet medical needs.
